Stone D.-H. Shi
LightNews LightNews
banner
stonedhshi.bsky.social
Stone D.-H. Shi
@stonedhshi.bsky.social
12 followers 39 following 25 posts
Analytical Scientist, Biological Medicine Developer, Mass Spectrometrist
Posts Replies Media Videos
stonedhshi.bsky.social
New article fully published in our journal: "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design" by authors from Fudan University in Shanghai, China. Congratulations.

doi.org/10.1093/abt/...

#Bispecific #LightChainSingleDomainAntibody
November 9, 2025 at 1:31 AM
stonedhshi.bsky.social
New article fully published in our journal: "Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase" by authors from Philochem and Philogen in Switzerland. Congratulations!

doi.org/10.1093/abt/...
November 9, 2025 at 1:21 AM
stonedhshi.bsky.social
A new paper just reached "corrected proof" stage on our journal @antibodytx.bsky.social titled "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design".

doi.org/10.1093/abt/...

#Antibody #SingleDomainAntibody #Bispecific #OpenAccess
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design
AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att
doi.org
October 24, 2025 at 4:43 AM
stonedhshi.bsky.social
Here is an interesting paper by my friend Diana Liu, in collaboration with one of my favorite mass spec software company Protein Metrics.

doi.org/10.1016/j.ta...

Automation streamlines peptide map preparation, analysis and reporting for biotherapeutic antibody characterization
October 24, 2025 at 4:36 AM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights
"The process using a synthetic library that generates multiple diverse human single domain antibodies" contributed by Mark A Tornetta from Tavotek Biotherapeutics.
academic.oup.com/abt/article/...
#Antibody #Therapeutics
October 7, 2025 at 12:48 PM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
New article alert: "CAR NK cell therapy for solid tumors: potential and challenges" contributed by Yanlin Yu and Mitchell Ho from NIH.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #CAR #Celltherapy
CAR NK cell therapy for solid tumors: potential and challenges
Statement of Significance This review highlights the promise of CAR NK cell therapy as a safer, off-the-shelf alternative to CAR-T cells for solid tumors.
academic.oup.com
October 8, 2025 at 12:50 PM
stonedhshi.bsky.social
Happy to see the special collection I worked on in the past year is completed and online now. Many thanks to Guest Editors Yunsong (Frank) Li of @elilillyandcompany.bsky.social and Qingyan Hu of @regeneron.com

#Formulation #Antibody #ADC #Lyo #OpenAccess

academic.oup.com/abt/pages/fo...
Special Collection: Formulation of Antibody-Based Therapeutics
Drug product formulation transforms active pharmaceutical ingredients into drug products, ensuring stability, manufacturability, efficacy, and patient safety. D
academic.oup.com
October 8, 2025 at 4:36 AM
stonedhshi.bsky.social
This practical advise review article, published earlier this year, has already been cited 8 times. It will be part of the formulation special collection our journal will launch next week.

doi.org/10.1093/abt/...

#Review #Lyo #Formulation #Practical
8 citations, 3546 views, 2 media mentions
September 28, 2025 at 1:55 AM
stonedhshi.bsky.social
I would like to highlight this high impact review article. Since publication just a few months ago, it has been cited multiple times , and downloaded over 16,000 times.

If you are interested in ADCs, this one is a must read!

#ADC #Conjugation #Review

doi.org/10.1093/abt/...
3 citations, 16498 views, 7 media mentions
September 28, 2025 at 1:44 AM
stonedhshi.bsky.social
New review article on our journal: Reprogramming the tumor microenvironment: synergistic mechanisms of antibody–drug conjugates and immune checkpoint inhibitors

doi.org/10.1093/abt/...

#OpenAccess #ADC #ICI #TME #irAE #IMER #Oncology
September 23, 2025 at 4:37 AM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
New Publication Alert: "CAR NK Cell Therapy for Solid Tumors: Potential and Challenges" from National Cancer Institute, National Institutes of Health.
academic.oup.com/abt/advance-...
CAR NK Cell Therapy for Solid Tumors: Potential and Challenges
Statement of Significance This review highlights the promise of CAR NK cell therapy as a safer, off-the-shelf alternative to CAR-T cells for solid tumors.
academic.oup.com
September 15, 2025 at 10:42 PM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
New Publication Alert: "Structure and function of therapeutic antibodies approved by the US FDA in 2024" from William R Strohl.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #FDA #mAbs
Structure and function of therapeutic antibodies approved by the US FDA in 2024
Abstract. In 2024, the FDA approved 47 new molecular entities (NMEs), including 15 therapeutic antibody-based molecules, marking the 30th anniversary of th
academic.oup.com
July 1, 2025 at 12:27 AM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
New Publication Alert: "Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells" from University of Ottawa.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #VHH #Nanobody #CAR-T
Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells
AbstractBackground. Production of chimeric antigen receptor T cell (CAR-T) therapies depends on antibody reagents to label, isolate, and expand T cell prod
academic.oup.com
August 11, 2025 at 9:09 PM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
🚀 Hot off the press!
We are excited to share the special collection:
"Antibody–Drug Conjugates in Cancer and Beyond",
published in Antibody Therapeutics (Impact Factor: 4.5).
📖 Read the full collection for free:
🔗 academic.oup.com/abt/pages/an...
#Antibody #Therapeutics #ADC
Special Collection: Antibody–Drug Conjugates in Cancer and Beyond
Antibody-drug conjugates (ADCs) are at the forefront of innovation in targeted cancer therapy, offering a highly effective strategy that combines the specificit
academic.oup.com
August 11, 2025 at 9:20 PM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
🚀 Insightful Review in Antibody Therapeutics(IF=4.5): Mapping the protein protein interactome in the tumor immune microenvironment
academic.oup.com/abt/article/...
August 27, 2025 at 12:24 AM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
”An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy“ contributed by researchers from Terasaki Institute for Biomedical Innovation.
academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs #MHC
An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy
Statement of Significance: Current peptide-based cancer immunotherapy is challenged with the limited availability of immunogenic epitopes. To facilitate th
academic.oup.com
August 27, 2025 at 10:55 PM
Reposted by Stone D.-H. Shi
antibodytx.bsky.social
"Connexin 43 hemichannels and related diseases"contributed by Yanfeng Zhang (AlaMab Therapeutics) and Jean X Jiang (University of Texas Health Science Center).
Free access of the full article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs
September 3, 2025 at 9:11 PM
stonedhshi.bsky.social
The Editorial of our Formulation Special Collection is now online. Many thanks to the guest editors Dr. Qingyan Hu of @regeneron.com and Dr. Frank Li of @elilillyandcompany.bsky.social.

doi.org/10.1093/abt/...

#Formulation #Antibody #mAb #ADC #Lyo #HighConcentration #Coformulation
Opportunities in formulation development of antibody-based therapeutics
Abstract. Drug product formulation transforms active pharmaceutical ingredients into drug products, ensuring stability, manufacturability, efficacy, and pa
doi.org
September 15, 2025 at 12:23 AM
stonedhshi.bsky.social
New Research (2025 Paper): "Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule" from Japan

doi.org/10.1093/abt/...

#CD30 #TNFRSF8 #Biparatopic #Bispecific #Oncology
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule
Statement of Significance: Thirty-six bivalent biparatopic antibodies targeting pairs of nine distinct topographical epitopes distributed over CD30 were de
doi.org
September 15, 2025 at 12:15 AM
stonedhshi.bsky.social
High Impact Research (2023 Paper): "AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains" by Dr. Jian Huang from University of Electronic Science and Technology of China.

doi.org/10.1093/abt/...

#Amyloidosis #Developability #Prediction
AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains
Statement of Significance: The amyloidogenic propensity of light chains is not only associated with disease but also the developability of the antibody. A
doi.org
September 15, 2025 at 12:10 AM
stonedhshi.bsky.social
High impact research (2023 Paper): "Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex" by Dr. Liusong Yin et al from SunHo.

doi.org/10.1093/abt/...

#PD1 #IL15 #Oncology
Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex
Statement of Significance: IAP0971 is a novel bifunctional PD1/IL15 immunocytokine that has demonstrated excellent anti-tumor efficacy and favorable safety
doi.org
September 15, 2025 at 12:05 AM
stonedhshi.bsky.social
New article “Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma” contributed by Karla Frietze Miller, Ph.D. from Skunkworx Bio.

doi.org/10.1093/abt/...

#mAbs #TIM4 #Oncology
Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma
Statement of Significance: We developed a rapid antibody discovery program using directed-protein engineering to develop a first in class anti-human T-cell
doi.org
September 15, 2025 at 12:01 AM
stonedhshi.bsky.social
I am happy to announce that we have selected the cover image of volume 8 issue 3, based on Dr. William Strohl's excellent review of 2024 FDA Approved Antibody Therapeutics. See the full article here: doi.org/10.1093/abt/...

Congratulations, Dr. Strohl, and thank you as always!!
August 9, 2025 at 4:12 PM
stonedhshi.bsky.social
This review of purification strategy of therapeutic proteins received 23 citations already.

#Downstream #Purification #TherapeuticProtein #mAba #FusionProtein #VHH #scFv
@antibodytx.bsky.social
Challenges and solutions for the downstream purification of therapeutic proteins
Statement of Significance: The diversity of protein structures has led to an increased complexity of product- and process-related impurities. The article s
doi.org
July 22, 2025 at 4:54 AM
stonedhshi.bsky.social
This article on the topic of smaller format ADCs for solid tumor treatment is getting quite a bit attention recently. Check it out!

#ADC #Oncology #SolidTumor
@antibodytx.bsky.social
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate
Statement of Significance: The research on ADCs is advancing toward an innovative transitional phase. Small antibody fragments or other structurally derive
doi.org
July 22, 2025 at 4:49 AM